Concordance Study of 3 Direct-to-Consumer Genetic-Testing Services

Kenta Imai, Larry J. Kricka,* and Paolo Fortina

1 Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; 2 Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Jefferson Medical College, Philadelphia, PA; * address correspondence to this author at: Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104. Fax 215-662-7529; e-mail kricka@mail.med.upenn.edu.

BACKGROUND: Several companies offer direct-to-consumer (DTC) genetic testing to evaluate ancestry and wellness. Massive-scale testing of thousands of single-nucleotide polymorphisms (SNPs) is not error free, and such errors could translate into misclassification of risk and produce a false sense of security or unnecessary anxiety in an individual. We evaluated 3 DTC services and a genomics service that are based on DNA microarray solution genotyping with hydrolysis probes (TaqMan® analysis) and compared the test results obtained for the same individual.

METHODS: We evaluated the results from 3 DTC services (23andMe, deCODEme, Navigenics) and a genomics-analysis service (Expression Analysis).

RESULTS: The concordance rates between the services for SNP data were >99.6%; however, there were some marked differences in the relative disease risks assigned by the DTC services (e.g., for rheumatoid arthritis, the range of relative risk was 0.9–1.85). A possible reason for this difference is that different SNPs were used to calculate risk for the same disease. The reference population also had an influence on the relative disease risk.

CONCLUSIONS: Our study revealed excellent concordance between the results of SNP analyses obtained from different companies with different platforms, but we noted a disparity in the data for risk, owing to both differences in the SNPs used in the calculation and the reference population used. The larger issues of the utility of the information and the need for risk data that match the user’s ethnicity remain, however.

Numerous companies now offer direct-to-consumer (DTC)3 (or direct access) genetic testing to evaluate ancestry, health, and wellness (1). This type of massive-scale testing of thousands of SNPs is a complex multi-step analytical procedure and thus is liable to error. Such errors could translate into, for example, a misclassification of risk that in turn could produce a false sense of security or unnecessary anxiety in an individual. A previous study that investigated the concordance of SNP data from 23andMe and Navigenics showed a level of agreement of 99.7% and some considerable differences in the assigned relative risk of disease (2). The objective of the present study was to undertake a more wide-ranging study. To this end, we evaluated 3 DTC services and a genomics service that used DNA microarray analysis or genotyping with hydrolysis probes (TaqMan® analysis) and compared the test results obtained for the same individual (3).

Samples obtained from the same healthy volunteer were tested at 3 DTC genetic-testing services (23andMe, Mountain View, CA; deCODEme, Reykjavik, Iceland; Navigenics, Foster City, CA) and a genomics-analysis service (Expression Analysis, Durham, NC).

Samples for the DTC services were collected according to their respective instructions and with the sample-collection kits provided. Saliva samples were sent to 23andMe and Navigenics, and buccal swabs were sent to deCODEme. For Expression Analysis, samples of DNA were extracted from whole blood in our laboratory with the chemagic Magnetic Separation Module robot (chemagic Biopolymer-Technologie). The platform used for the analysis depended on the service. 23andMe and deCODEme used DNA microarrays from Illumina, with the HumanHap 550 + Genotyping BeadChip (approximately 5.78 × 10⁶ SNPs analyzed) and Human1M-Duo DNA Analysis BeadChip (approximately 1.1 × 10⁶ SNPs), respectively. Navigenics used Applied Biosystems TaqMan® Genotyping Assays (approximately 120 SNPs). Expression Analysis used 2 platforms: the Affymetrix Genome-Wide Human SNP Array 6.0 (approximately 9.09 × 10⁶ SNPs) and the Illumina HumanOmniExpress BeadChip (approximately 7.33 × 10⁷ SNPs). The DTC services performed the disease risk analyses. 23andMe and deCODEme allow customers to change their ancestry information for the disease risk analysis by using the Web page for selecting the optimum reference population. The ancestry information for Navigenics is fixed, however, and their analysis primarily uses the reference population.


3 Nonstandard abbreviations: DTC, direct-to-consumer; SNP, single-nucleotide polymorphism.
of Americans with northern and western European ancestry. To better compare the results from 23andMe and deCODEme with those from Navigenics, we selected “Northern Europe” for 23andMe and “European Ancestry” for deCODEme.

We used Microsoft Access to compare the SNP data. Data in the .csv file format were imported directly into Access. Other data formats were first converted into .csv format (e.g., Affymetrix .cel files). For Navigenics, we copied the raw data directly from the Web page to obtain a .csv file. Some minor editing was required in some cases (e.g., remove header, convert minus to plus strand, or alphabetize the SNP list). We created a query in Access’s Design View and compared pairs of tables to determine the number of SNPs common to the 2 files and the number of matching SNPs. The concordance rate was calculated by dividing the number of matched SNPs by the number of SNPs compared.

We compared the relative disease risks obtained from the DTC services. 23andMe and deCODEme provide relative disease risks on their Web pages. For Navigenics, we calculated relative risk by dividing the individual risk by the mean risk of the reference population. For deCODEme, we also investigated the influence of the reference population on relative disease risk by changing the ancestry information on the Web page.

Table 1 summarizes the concordance rates for the SNP data. The concordance rates were >99.6% in all the comparisons. In particular, the concordance rates for comparing Illumina microarrays were >99.9%. The concordance rates between Illumina and Affymetrix microarrays were 99.6%–99.7%. Concordance rates for SNP data for comparisons of DNA microarray analysis and TaqMan analysis were 100% in all of the comparisons, although the numbers of SNPs compared were much smaller (<100 SNPs).

Fig. 1 shows the variation in relative disease risk assigned by the different DTC services. There were some marked differences in relative disease risk (see the Data Supplement that accompanies the online version of this Brief Communication at http://www.clinchem.org/content/vol57/issue3 for SNPs used in determining risk and the statistical significance of differences in the risk estimates).

For example, the estimates for rheumatoid arthritis indicate a protective effect in 1 case (relative risk, 0.9) and a deleterious effect of the genotype on disease risk in the other 2 cases (relative risk, 1.3 and 1.85). Similarly, the disease risk for atrial fibrillation varied from 0.8 to 1.8. For age-related macular degeneration, deCODEme and Navigenics results produced relative disease risk values of approximately 1.1 (1.10 and 1.13, respectively); however, 23andMe produced a relative risk for this disease of 1.61. Fig. 1 also shows the number of SNPs used in the calculation of relative disease risk, and an examination of this figure reveals that the number of SNPs used in the risk calculation depended on the service. This finding might be one of the reasons for the differences in evaluations of relative disease risk. In addition, relative disease risks varied considerably, depending on the ancestry information. In the case of the deCODEme results, for example, the relative disease risk for rheumatoid arthritis was 1.86 when we used “European Ancestry”; however, the value changed to 1.15 when we used “African Ancestry.” The corresponding relative risks for colorectal cancer were 1.01 and 1.46, respectively.

DTC genetic testing is a highly controversial area, and several recent reports (4,5) and statements by professional societies (6) have addressed this type of testing.

Concerns have been voiced over the lack of involvement of a clinician or genetic counselor in such testing (7), the regulation of such tests (8,9), ethical and legal issues (10,11), the variance in and the validity of risk
assessment (2, 12), and the reliability of the overall analytical process and the possibility of genotyping errors (13–15).

Our study found a >99.6% concordance in SNP genotypes among 3 DTC services (23andMe, deCODEme, Navigenics) and a genomics-analysis service (Expression Analysis). This result agrees with a previous study that found a 99.7% concordance between DTC tests performed by 2 providers (23andMe and Navigenics) (2). Although this degree of concordance is very high, 100% accuracy must be the goal, because an error in the base call for a single SNP could produce a change in risk classification leading to a false sense of security or to an incorrect indication of increased risk.

The validity and importance of risk assessed by genotyping is a highly charged issue (12). We assessed the influence of ethnicity on risk classification. For some DTC services, the risk calculated applied only to Caucasian individuals, thus leading to the possibility of a misleading risk assessment for non-Caucasian individuals. Our investigation into the effect of selecting ethnicities different from that of the study individual on the risk calculations revealed the potential magnitude of this problem.

In conclusion, our study has revealed excellent concordance between the results of SNP analyses from different companies performed on different platforms. Nonetheless, for some of the diseases investigated, there is large variation in relative disease risks reported by the different companies. The larger issues of the utility of the information and the need for risk data that match the user’s ethnicity remain.

**Author Contributions:** All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

**Authors’ Disclosures or Potential Conflicts of Interest:** No authors declared any potential conflicts of interest.

**Role of Sponsor:** The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.
References


Previously published online at DOI: 10.1373/clinchem.2010.158220